Founded in Newton, Massachusetts, ReLive is a biotechnology company dedicated to advancing orthopedic sports medicine and plastic and reconstructive surgery through regenerative medicine and cell therapy. The company's core mission is to provide personalized, autologous cell therapies for the treatment of joint cartilage injuries and defects, aiming to help patients return to their active lifestyles. ReLive's innovative platform focuses on advanced cartilage repair, restoration, and transplant procedures that promise long-term outcomes without artificial elements.
ReLive has garnered attention for its pioneering work in regenerative cell therapies, attracting notable investors and collaborations within the biotech and medical communities. The company’s achievements include the development of cutting-edge techniques for cartilage reconstruction, which have shown significant promise in clinical settings. By focusing on personalized medicine and leveraging the latest advancements in cell therapy science, ReLive is making a substantial impact on the field of orthopedic surgery and regenerative medicine.
